Kamada Ltd. (KMDA)
Chart Events
Performance Outlook
| Previous Close | 5.27 |
| Open | 5.25 |
| Bid | 5.23 x 800 |
| Ask | 5.32 x 1100 |
| Day's Range | 5.21 - 5.31 |
| 52 Week Range | 5.17 - 8.85 |
| Volume | 15,873 |
| Avg. Volume | 49,736 |
| Market Cap | 237.662M |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 16.54 |
| EPS (TTM) | 0.32 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Zacks
New Strong Sell Stocks for August 25th
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
- Zacks
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
Second Quarter 2021 Revenues were $24.2 MillionIn Connection with the Transition of GLASSIA® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an Approximately 10% Annual Labor Cost Reduction Pivotal Phase 3 InnovAATe Trial for Inhaled AAT for Treatment of Alpha-1 Antitrypsin Deficiency Continues to Advance as Kamada Evaluates Strategic Partnering OpportunitiesOngoing Expansion of Plasma Collection Capacity at Recently Acquired U.S. Plasma C
